Incyte (INCY) Stock Forecast, Price & News

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 1 sell rating, 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View INCY analyst ratings or view top-rated stocks.

18 brokerages have issued 12-month price targets for Incyte's stock. Their INCY share price forecasts range from $61.00 to $100.00. On average, they anticipate the company's share price to reach $82.00 in the next year. This suggests a possible upside of 39.8% from the stock's current price.
View analysts price targets for INCY or view top-rated stocks among Wall Street analysts.

Incyte's stock was trading at $80.32 at the beginning of the year. Since then, INCY shares have decreased by 27.0% and is now trading at $58.64.
View the best growth stocks for 2023 here.

Incyte saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 6,480,000 shares, an increase of 13.5% from the August 31st total of 5,710,000 shares. Based on an average trading volume of 1,580,000 shares, the short-interest ratio is presently 4.1 days.
View Incyte's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our INCY earnings forecast.

Incyte Co. (NASDAQ:INCY) issued its earnings results on Tuesday, August, 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.08. The biopharmaceutical company had revenue of $954.61 million for the quarter, compared to analyst estimates of $920.18 million. Incyte had a trailing twelve-month return on equity of 9.25% and a net margin of 10.43%.

ETFs with the largest weight of Incyte (NASDAQ:INCY) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), IQ U.S. Mid Cap R&D Leaders ETF (MRND), Virtus LifeSci Biotech Products ETF (BBP), First Trust Nasdaq Pharmaceuticals ETF (FTXH), ASYMmetric Smart S&P 500ETF (ASPY), American Century STOXX U.S. Quality Growth ETF (QGRO) and Strategas Global Policy Opportunities ETF (SAGP).

22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Incyte's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.66%), State Street Corp (4.40%), Renaissance Technologies LLC (2.15%), Geode Capital Management LLC (1.82%), Bellevue Group AG (1.18%) and Northern Trust Corp (0.90%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Michael James Morrissey, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends.

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INCY stock can currently be purchased for approximately $58.64.

Incyte (NASDAQ:INCY) has a market capitalization of $13.14 billion and generates $3.39 billion in revenue each year. The biopharmaceutical company earns $340.66 million in net income (profit) each year or $1.63 on an earnings per share basis.

The company employs 2,324 workers across the globe.

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The official website for the company is www.incyte.com. The biopharmaceutical company can be reached via phone at (302) 498-6700, via email at mbooth@incyte.com, or via fax at 302-425-2750.